Placenta Accreta, Third TrimesterNCT07236060
Ultrasound Model to Help Differentiate Between Placenta Accreta Spectrum and Uterine Dehiscence in 3rd Trimester Pregnancies
An observational study of Placenta Accreta, Third Trimester and Uterine Scar Dehiscence, run by Assiut University.
Trial summary
By using 2d Ultrasound on 3rd trimester pregnant women, a model is made to help differentiate between placenta accreta spectrum and uterine scar dehiscence before operative action to help prepare multi-disciplinary steps if needed Read more about this study
- Who is it for?
- Ages 18 to 50 years, women only
- Conditions the study is for
- Placenta Accreta, Third Trimester, Uterine Scar Dehiscence
- What is being tested?
- 2D ultrasound doppler
- Type of treatment
- Medical device
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 15 Nov 2025to 15 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Women only
- No healthy volunteers
- Adult
Study population: Female patients admitted to women health hospital, Assiut university, Assiut
Who may be able to join
- Women in 3rd trimester pregnancy with low lying placenta previa
- History of 1 or more C-section
- Patients planning to deliver baby in Assiut women health hospital
- Willing and able to participate
Who cannot join
- Antepartum Hemorrhage(sever attack) as it hinders time for accurate diagnosis and calling expert team of diagnosis
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Placenta Accreta Spectrum VS Uterine Scar Dehiscence: Accurate Ultrasound Model in 3rd Trimester Pregnancies for Percise Diagnosis
By using 2d Ultrasound on 3rd trimester pregnant women, a model is made to help differentiate between placenta accreta spectrum and uterine scar dehiscence before operative action to help prepare multi-disciplinary steps if needed
Read the detailed description
A cross-sectional observational study
- Being tested
- 2D ultrasound doppler
- Medical subject headings
- Placenta Accreta
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
2D ultrasound dopplerDevice
using 2d ultrasound doppler to form a model that will help distinguish between placenta accreta spectrum and uterine scar dehiscence pre-operatively
What is being measured
The primary outcome is the main question the study is designed to answer.
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Placental site
Measured: (gestational age 28wk-full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: placental thickness
Measured: (gestational age 28wk- full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: placental size
Measured: (gestational age 28wk- fullterm) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: placental lacunae
Measured: (gestational age 28wk-full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Loss of placental hypoechoic zone
Measured: (gestattional age 28wk-full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Mean systolic velocity in both uterine arteries
Measured: (gestational age 28wks-full term) till time of operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uteroplacental interface
Measured: (gestational age 28wks- full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uterovesical interface
Measured: (gestational age 28wks- full term) ill operation
Secondary outcomes (8)
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental site
Measured: (gestational age 28wk- fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental size
Measured: (gestational age 28wk- full term)till the operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental thickness
Measured: (gestational age 28wk-full term) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental lacunae
Measured: (gestational age 28wk- fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Loss of placental hypoechoic zone
Measured: (gestational age 28wks - fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Mean systolic velocity in both uterine arteries
Measured: (gestational age 28wk- fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uteroplacental interface
Measured: (gestational age 28wk- fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uterovesical interface
Measured: (gestational age 28wk-full term) till operation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Nov 2025
- Study start15 Nov 2025 (estimated)
- Primary completion15 Nov 2026 (estimated)
- Study completion15 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Placenta Accreta, Third TrimesterStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mostafa Ahmed Mohammed Refaat Askalany, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07236060
- Sponsor's protocol ID
- 042025201333
- Status last verified
- Sep 2025
- First submitted
- 30 Sep 2025
- Last updated
- 19 Nov 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Placenta Accreta Spectrum VS Uterine Scar Dehiscence: Accurate Ultrasound Model in 3rd Trimester Pregnancies for Percise Diagnosis
- ClinicalTrials.gov ID
- NCT07236060
- Acronym / sponsor ID
- 042025201333
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 15 Nov 2025 (estimated)
- Primary completion
- 15 Nov 2026 (estimated)
- Study completion
- 15 Dec 2026 (estimated)
- First posted
- 19 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
By using 2d Ultrasound on 3rd trimester pregnant women, a model is made to help differentiate between placenta accreta spectrum and uterine scar dehiscence before operative action to help prepare multi-disciplinary steps if needed
Detailed description
A cross-sectional observational study
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Female patients admitted to women health hospital, Assiut university, Assiut
Key inclusion criteria (4 listed)
- Women in 3rd trimester pregnancy with low lying placenta previa
- History of 1 or more C-section
- Patients planning to deliver baby in Assiut women health hospital
- Willing and able to participate
Key exclusion criteria (1 listed)
- Antepartum Hemorrhage(sever attack) as it hinders time for accurate diagnosis and calling expert team of diagnosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 2D ultrasound dopplerusing 2d ultrasound doppler to form a model that will help distinguish between placenta accreta spectrum and uterine scar dehiscence pre-operatively | Device | – |
Primary outcome
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Placental site
Time frame: (gestational age 28wk-full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: placental thickness
Time frame: (gestational age 28wk- full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: placental size
Time frame: (gestational age 28wk- fullterm) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: placental lacunae
Time frame: (gestational age 28wk-full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Loss of placental hypoechoic zone
Time frame: (gestattional age 28wk-full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Mean systolic velocity in both uterine arteries
Time frame: (gestational age 28wks-full term) till time of operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uteroplacental interface
Time frame: (gestational age 28wks- full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uterovesical interface
Time frame: (gestational age 28wks- full term) ill operation
8 secondary outcomes
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental site
Time frame: (gestational age 28wk- fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental size
Time frame: (gestational age 28wk- full term)till the operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental thickness
Time frame: (gestational age 28wk-full term) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental lacunae
Time frame: (gestational age 28wk- fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Loss of placental hypoechoic zone
Time frame: (gestational age 28wks - fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Mean systolic velocity in both uterine arteries
Time frame: (gestational age 28wk- fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uteroplacental interface
Time frame: (gestational age 28wk- fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uterovesical interface
Time frame: (gestational age 28wk-full term) till operation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Nov 2025.
- Individual participant dataSharing planned: No
Related trials for Placenta Accreta, Third Trimester
Not yet recruitingObservational study
Ultrasound Scoring System for Diagnosis and Prediction of Severity and Surgical Outcomes of Placenta Accreta Spectrum
Placenta Accreta, Third Trimester
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Placenta Accreta, Third Trimester and Uterine Scar Dehiscence, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mostafa A Askalany (+201022554284, mostafaaskalany90@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Placental site (time frame: (gestational age 28wk-full term) till operation). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Nov 2025; AzTrials last refreshed its copy on 6 Nov 2026.